These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 4418704)

  • 1. Effects of levodopa therapy in patients with Parkinson's disease: statistical evidence for reduced tolerance to levodopa in the elderly.
    Grad B; Wener J; Rosenberg G; Wener SW
    J Am Geriatr Soc; 1974 Nov; 22(11):489-94. PubMed ID: 4418704
    [No Abstract]   [Full Text] [Related]  

  • 2. [Changes of blood pressure, pulse and electrolytes following long-term treatment of Parkinsonism using Ro 8-0576 (L-Dopa and decarboxylase inhibitor)].
    Eisenlohr JJ; Gehlen W
    Nervenarzt; 1975 Mar; 46(3):128-35. PubMed ID: 805381
    [No Abstract]   [Full Text] [Related]  

  • 3. Cardiovascular effects of levodopa in aged versus younger patients with Parkinson's disease.
    Wener J; Rosenberg G; Grad B; Wener S
    J Am Geriatr Soc; 1976 Apr; 24(4):185-8. PubMed ID: 1254882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low-dose, slow-increase bromocriptine in patients with progressive Parkinson's disease and complications of levodopa therapy.
    Stern MB; Vernon GM; Gollomp SM; Hurtig HI
    Bull Clin Neurosci; 1986; 51():52-6. PubMed ID: 3455244
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamics of the hypotensive effect of levodopa in parkinsonian patients.
    Irwin RP; Nutt JG; Woodward WR; Gancher ST
    Clin Neuropharmacol; 1992 Oct; 15(5):365-74. PubMed ID: 1423336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A controlled study comparing trihexyphenidyl hydrochloride plus levodopa with placebo plus levodopa in patients with Parkinson's disease.
    Martin WE; Loewenson RB; Resch JA; Baker AB
    Neurology; 1974 Oct; 24(10):912-9. PubMed ID: 4606107
    [No Abstract]   [Full Text] [Related]  

  • 7. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Results of L-dopa treatment of parkinsonism].
    Dowzenko A; Buksowicz C; Kuran W
    Neurol Neurochir Pol; 1975; 9(2):153-8. PubMed ID: 1153050
    [No Abstract]   [Full Text] [Related]  

  • 9. Domperidone and levodopa in Parkinson's disease.
    Shindler JS; Finnerty GT; Towlson K; Dolan AL; Davies CL; Parkes JD
    Br J Clin Pharmacol; 1984 Dec; 18(6):959-62. PubMed ID: 6529536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ropinirole without levodopa in Parkinson's disease.
    Vidailhet MJ; Bonnet AM; Belal S; Dubois B; Marle C; Agid Y
    Lancet; 1990 Aug; 336(8710):316-7. PubMed ID: 1974005
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the effects of bromocriptine and levodopa in Parkinson's disease.
    Godwin-Austen RB; Smith NJ
    J Neurol Neurosurg Psychiatry; 1977 May; 40(5):479-82. PubMed ID: 330825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment of Parkinson's disease with levodopa and a dopa decarboxylase inhibitor].
    Londoõ R
    Neurol Neurocir Psiquiatr; 1976; 17(4):293-300. PubMed ID: 1018729
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Levodopa and decarboxylase inhibitors in Parkinson's disease].
    Gilland O
    Lakartidningen; 1977 Jan; 74(1-2):37-40. PubMed ID: 318722
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of levodopa therapy in Parkinson's disease. II. Measurement of behavioural changes.
    Radbill R; Rosenberg G; Schwartz A
    Can Med Assoc J; 1974 Dec; 111(11):1218-22. PubMed ID: 4434291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early and late effects of levodopa on the cardiovascular system in Parkinson's disease. A paired study.
    Ballantyne JP
    J Neurol Sci; 1973 May; 19(1):97-103. PubMed ID: 4715025
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: Long-term assessment of levodopa therapy in Parkinson's disease.
    Barbeau A
    Can Med Assoc J; 1975 Jun; 112(12):1379-80. PubMed ID: 1139474
    [No Abstract]   [Full Text] [Related]  

  • 17. [Benefit of L-DOPA-without-DCI (decarboxylase inhibitor) therapy on wearing-off phenomenon in advanced stages of Parkinson's disease patients].
    Hironishi M; Miwa H; Kondo T
    No To Shinkei; 2002 Feb; 54(2):127-32. PubMed ID: 11889758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Secondary effects of prolonged levodopa therapy in Parkinson's disease].
    Peiró Grasa A; Grau-Veciana JM
    Med Clin (Barc); 1985 Jun; 85(3):88-91. PubMed ID: 4021630
    [No Abstract]   [Full Text] [Related]  

  • 19. "Early" initiation of levodopa treatment does not promote the development of motor response fluctuations, dyskinesias, or dementia in Parkinson's disease.
    Cedarbaum JM; Gandy SE; McDowell FH
    Neurology; 1991 May; 41(5):622-9. PubMed ID: 2027475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.